This project wants to determinate whether there is a relationship between the N680S polymorphism genotype of the FSHR gene and the nature of the FSH used in controlled ovarian stimulation. It is a non-interventional, observational, cross-sectional and retrospective, national and multicenter study, in which a genetic test will be carried out to determine the genotype of the N680S polymorphism in samples of blood of patients who have undergone two cycles of controlled ovarian stimulation in the last 8 months.
Description: Number of oocytes retrieved in each IVF/ICSI cycle with controlled ovarian stimulation used different nature of the FSH in each one (human FSH and recombinant FSH).
Measure: Oocytes retrieved Time: Through study completion, an average of 1 yearDescription: Genotype of the N680S polymorphism of the FSHR gene will be tested on blood samples
Measure: Genotype of the N680S polymorphism of the FSHR gene Time: Through study completion, an average of 1 yearDescription: Genotype of the N312S polymorphism of the LHCGR gene will be tested on blood samples
Measure: Genotype of the N312S polymorphism of the LHCGR gene Time: Through study completion, an average of 1 yearCase-Only
There are 2 SNPs
Genotype of the N312S polymorphism of the LHCGR gene. --- N312S ---
Genotype of the N312S polymorphism of the LHCGR gene will be tested on blood samples. --- N312S ---
Study of the N680S Polymorphism of the FSHR Gene and Its Relationship With the Type of Gonadotropin Used in Controlled Ovarian Stimulation. --- N680S ---
N680S Polymorphism of the FSHR Gene and Its Relationship With the Type of Gonadotropin Used in COS This project wants to determinate whether there is a relationship between the N680S polymorphism genotype of the FSHR gene and the nature of the FSH used in controlled ovarian stimulation. --- N680S ---
N680S Polymorphism of the FSHR Gene and Its Relationship With the Type of Gonadotropin Used in COS This project wants to determinate whether there is a relationship between the N680S polymorphism genotype of the FSHR gene and the nature of the FSH used in controlled ovarian stimulation. --- N680S --- --- N680S ---
It is a non-interventional, observational, cross-sectional and retrospective, national and multicenter study, in which a genetic test will be carried out to determine the genotype of the N680S polymorphism in samples of blood of patients who have undergone two cycles of controlled ovarian stimulation in the last 8 months. --- N680S ---
Number of oocytes retrieved in each IVF/ICSI cycle with controlled ovarian stimulation used different nature of the FSH in each one (human FSH and recombinant FSH).. Genotype of the N680S polymorphism of the FSHR gene. --- N680S ---
Genotype of the N680S polymorphism of the FSHR gene will be tested on blood samples. --- N680S ---
Inclusion criteria: - Signature of Informed Consent - Age ≤ 37 years - BMI < 30 kg/m2 - Antral follicles count 1st cycle COS = 5-15 - Antimüllerian hormone basal 1st cycle COS > 1,1 ng/ml and < 3,1 ng/ml - COS protocol: equal starting dose in the 2 cycles of COS (150-225 UI/day) with dose adjustment from the 5th day of COS; pituitary suppression protocol in the 2 cycles of COS with GnRH antagonist with onset when ≥ 1 follicle of ≥ 14 mm in diameter or E2 ≤ 600 pg/ml; and triggering with hCGr or GnRH agonist - Optional the use of oral contraceptives (OC) (however, same in the 2 cycles) - 4-9 recovered oocytes in the 1st cycle of COS - ≤ 6 months between the 2 cycles of COS Exclusion criteria: - Use of the LH activity during the cycles of COS - Presence of severe male factor - Grade III-IV endometriosis - Patients with polycystic ovary syndrome, a history of uterine or ovarian surgeries, hydrosalpinx visible by ultrasound, or uterine fibroids measuring > 30 mm - Major systemic or uncontrolled endocrine-metabolic diseases affecting the pituitary gland, the thyroid gland, the adrenal glands, the pancreas, the liver, or the kidneys Inclusion criteria: - Signature of Informed Consent - Age ≤ 37 years - BMI < 30 kg/m2 - Antral follicles count 1st cycle COS = 5-15 - Antimüllerian hormone basal 1st cycle COS > 1,1 ng/ml and < 3,1 ng/ml - COS protocol: equal starting dose in the 2 cycles of COS (150-225 UI/day) with dose adjustment from the 5th day of COS; pituitary suppression protocol in the 2 cycles of COS with GnRH antagonist with onset when ≥ 1 follicle of ≥ 14 mm in diameter or E2 ≤ 600 pg/ml; and triggering with hCGr or GnRH agonist - Optional the use of oral contraceptives (OC) (however, same in the 2 cycles) - 4-9 recovered oocytes in the 1st cycle of COS - ≤ 6 months between the 2 cycles of COS Exclusion criteria: - Use of the LH activity during the cycles of COS - Presence of severe male factor - Grade III-IV endometriosis - Patients with polycystic ovary syndrome, a history of uterine or ovarian surgeries, hydrosalpinx visible by ultrasound, or uterine fibroids measuring > 30 mm - Major systemic or uncontrolled endocrine-metabolic diseases affecting the pituitary gland, the thyroid gland, the adrenal glands, the pancreas, the liver, or the kidneys In Vitro Fertilization Controlled Ovarian Stimulation The investigators want to investigate whether the N680S polymorphism of the FSRH gene could affects ovarian response with different nature of the FSH used (human FSH and recombinant FSH) in patients undergoing two consecutive cycles of IVF/ICSI with controlled ovarian stimulation. --- N680S ---